Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)

Blood

Volumn 100, Issue 13, 2002, Pages 4325-4336

  Byrd, John C ^a   Mrózek, Krzysztof ^a   Dodge, Richard K ^b   Carroll, Andrew J ^c   Edwards, Colin G ^a   Arthur, Diane C ^d   Pettenati, Mark J ^e   Patil, Shivanand R ^f   Rao, Kathleen W ^g   Watson, Michael S ^h   Koduru, Prasad R K ⁱ   Moore, Joseph O ^j   Stone, Richard M ^k   Mayer, Robert J ^k   Feldman, Eric J ^l   Davey, Frederick R ^m   Schiffer, Charles A ⁿ   Larson, Richard A ^o   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CALGB Statistical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁿ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0037114753     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0772     Document Type: Article

References (59)

1. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984;11:332-350.
2. Arthur DC, Berger R, Golomb HM, et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet. 1989;40:203-216.
3. Fenaux P, Preudhomme C, Laï JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases. Br J Haematol. 1989;73:61-67.
4. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
5. Stasi R, Del Poeta G, Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet. 1993;67:28-34.
6. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498.
7. Ferrant A, Doyen C, Delannoy A, et al. Karyotype in acute myeloblastic leukemia: Prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant. 1995;15:685-690.
8. Keating S, Suciu S, de Witte T, et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1996;17:993-1001.
9. Mrózek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11 q23: A Cancer and Leukemia Group B study. Blood. 1997;90:4532-4538.
10. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
11. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
12. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767-3775.
13. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
14. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:19-47.
15. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
16. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
17. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
18. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood. 1999;93:4131-4143.
19. Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: The APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001;48(suppl 1):S65-S71.
20. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
21. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
22. Döhner H, Arthur DC, Ball ED, et al. Trisomy 13: A new recurring chromosome abnormality in acute leukemia. Blood. 1990;76:1614-1621.
23. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
24. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
25. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325-329.
26. Mayer RJ, Schiffer CA, Peterson BA, et al. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: A progress report from the CALGB. Semin Oncol. 1987;14(suppl 1):25-31.
27. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
28. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671-1677.
29. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood. 1997;89:780-788.
30. Moore JO, Powell B, Velez-Garcia E, et al. A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients <60 years with acute myeloid leukemia: CALGB 9222 [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1997;16:14a.
31. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S Karger; 1995.
32. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
33. Armitage P. Statistical Methods in Medical Research. London, United Kingdom: Blackwell Scientific Publications; 1971.
34. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
36. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
37. Simon R, Lee YJ. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep. 1982;66:37-42.
38. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley and Sons; 1989.
39. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
40. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients. Br J Haematol. 2001;112:118-126.
41. Schoch C, Haase D, Fonatsch C, et al. The significance of trisomy 8 in de novo acute myeloid leukaemia: The accompanying chromosome aberrations determine the prognosis. Br J Haematol. 1997;99:605-611.
42. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288-1295.
43. Wiernik PH, Kim H, Gundacker H, et al. Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukemia (AML) with t(15;17), t(8;21) or inv(16)/t(16;16) [abstract]. Blood. 2001;98:457a.
44. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial. Br J Haematol. 2000;111:801-806.
45. Hernández JM, Martin G, Gutiérrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol: A report of the Spanish group PETHEMA. Haematologica. 2001;86:807-813.
46. Odero MD, Carlson KM, Calasanz MJ, Rowley JD. Further characterization of complex chromosomal rearrangements in myeloid malignancies: Spectral karyotyping adds precision in defining abnormalities associated with poor prognosis [letter]. Leukemia. 2001;15:1133-1136.
47. Mrózek K, Heinonen K, Theil KS, Bloomfield CD. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q and 22q. Genes Chromosomes Cancer. 2002;34:137-153.
48. Hollings PE, Cochrane J, Bowen JA, Rosman I, Fitzgerald PH. Growth characteristics in vitro of myeloid leukaemic cells with t(6;9). Leuk Lymphoma. 1995;17:281-288.
49. Alsabeh R, Brynes RK, Slovak ML, Arber DA. Acute myeloid leukemia with t(6;9)(p23;q34): Association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997;107:430-437.
50. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
51. Marlton P, Keating M, Kantarjian H, et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995;9:965-971.
52. Mrózek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol. 2001;19:2482-2492.
53. Kolitz JE, George SL, Dodge RK, et al. Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia (AML) < 60 years in first complete remission (CR): Results of CALGB 9621 [abstract]. Blood. 2001;98:688a.
54. Farag SS, Archer KJ, Mrózek K, et al. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002;21:1041-1051.
55. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
56. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res. 2001;61:7233-7239.
57. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58:55-59.
58. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14:796-804.
59. Byrd JC, Mrózek K, Dodge R, et al. Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: Results from CALGB 8461 [abstract]. Blood 2001;98:457a.